Breast carcinoma remains the most common malignancy of women around the world, and despite the advances in the early diagnosis and adjuvant treatment of this disease, many women still relapse with ...
The oncolytic virus therapy – also being developed by French biotech Transgene – failed to show any additional benefit when added to treatment with Bayer/Amgen’s targeted therapy Nexavar ...
As more United States drug price changes have come to light this month, it remains clear that companies are tamping down ...
AZ is comparing the tremelimumab/Imfinzi regimen to standard first line treatment with Bayer’s targeted HCC drug Nexavar (sorafenib) in the phase 3 HIMALAYA trial, which is due to read out later ...
Alvotech and Teva announced that the Food and Drug Administration has accepted for review Biologics License Applications for ...
1 For overall survival (OS), the combination of nivolumab plus ipilimumab showed a significant improvement in median OS compared with lenvatinib (Lenvima) or sorafenib (Nexavar) at 23.7 vs 20.6 months ...
The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
1 For overall survival (OS), the combination of nivolumab plus ipilimumab showed a significant improvement in median OS compared with lenvatinib (Lenvima) or sorafenib (Nexavar) at 23.7 vs 20.6 months ...